AI assistant
STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2020
Oct 20, 2020
62616_rns_2020-10-20_7be4740a-d775-4633-9772-6ead94d47245.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [136 x 45] intentionally omitted <==
October 20, 2020
BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR
Dear Madam/ Sir,
Sub: Press Release
Please find attached Press Release issued by the Company titled:
“Strides receives USFDA approval for Ethacrynic Acid Tablets”
Thanks & Regards,
For Strides Pharma Science Limited,
==> picture [114 x 47] intentionally omitted <==
Manjula Ramamurthy Company Secretary
==> picture [85 x 83] intentionally omitted <==
Encl. As above
==> picture [479 x 52] intentionally omitted <==
Press Release October 20, 2020
Strides receives USFDA approval for Ethacrynic Acid Tablets
To be marketed by Strides Pharma Inc. in the US market
Bengaluru, October 20, 2020 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Edecrin[®] Tablets, 25 mg, of Bausch Health Americas, Inc.
According to IQVIA MAT August 2020 data, the US market for Ethacrynic Acid Tablets USP, 25 mg is approximately US$ 14 Mn. The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.
The company has 126 cumulative ANDA filings with USFDA of which 92 ANDAs have been approved and 34 are pending approval.
About Ethacrynic Acid Tablets
Ethacrynic acid is in a class of medications called diuretics ('water pills'). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease.
About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com
For further information, please contact:
| or further information,please contact: | |
|---|---|
| Strides | Corporate Communication |
| Badree Komandur | Usha Iyer:+91 9987444106 |
| Executive Director – Finance & Group CFO | Email: [email protected] |
| +91 80 6784 0747 | |
| Investor Relations | PR Consultancy |
| Sandeep Baid:+91 80 6784 0791 | Fortuna PR |
| Email: [email protected] | K Srinivas Reddy: +91 90005 27213 |
| [email protected] | |
| K Priya: +91 95354 25418 | |
| [email protected] |
Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560 076